Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Gaucher disease
Biotech
Syncona merges Freeline, SwanBio into new gene therapy biotech
Spur’s pipeline will feature Freeline’s Gaucher disease program FLT201, as well as SwanBio’s phase 1/2 program for adrenomyeloneuropathy.
James Waldron
Jun 17, 2024 11:01am
Avrobio hopes to get investors back on gene therapy bandwagon
Dec 7, 2022 7:30am
Lilly doubles down on Prevail buy with $700M research hub
Feb 22, 2022 9:34am
Avrobio ditches Fabry, eyes 2023 trials for other gene therapies
Jan 4, 2022 10:08am
Vanqua nabs $85M from Lilly, OrbiMed, others for Gaucher, PD, AD
Sep 14, 2021 7:00am
Avrobio posts data on first Gaucher gene therapy patient
Nov 17, 2020 8:18am
